Amgen

Open: 234.89 Close: 234.11 Change: -0.78

12 lessons that an AI found about Amgen Company Inc Stock after reading internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, target, TScan, potential, investor, announce, Inc, and the most common words in the summary are: amgen, stock, inc, news, market, price, amgn, . One of the sentences in the summary was: Entera Bio, a former partner of Amgen, announced that both were ending a research …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen will use TScans target discovery platform to identify potential targets for Crohns disease. Entera Bio, a former partner of Amgen, announced that both were ending a research collaboration.

Today's News

Amgen will use TScans target discovery platform to identify potential targets for Crohns disease. Entera Bio, a former partner of Amgen, announced that both were ending a research collaboration that was first announced in 2018. Amgen Inc. is reviewing the complaint and has previously said that the allegations are without merit and overstated by billions of dollars. The complaint alleges that Amgens stock share price fell by 6.5% on August 4, 2021, and 4.3% on April 28, 2022, because the company waited until those dates to share the potential tax liability. Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) Such investors are advised to contact Ro... Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. May 3, 2023. Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. Such investors are advised to contact Rob... Kessler Topaz Meltzer & Check, LLP reminds Amgen inc. (amgn) shareholders of securities fraud class action lawsuit. Kessler Topz Meltzer and Check, LLC reminds investors that a securities class action. lawsuit has been filed in the United States District Court for the Southern District of New York. Third-quarter sales of Amgens new KRAS inhibitor Lumakras likely to have been higher than $77 million recorded in the second quarter. Amgen has a partnership with AstraZeneca AZN for Tezspire. Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohns disease. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan. TScan to receive $30 million up front with potential development and commercial payments of $500 million. Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) Amgen : 234.11 (-0.14%) Biotech ETFs Pop on M&A Resurgence Zacks. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen and TScan Therapeutics announce collaboration to identify novel targets in Crohns disease. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights. Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohns disease. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan. TScan to Receive $30 million Upfront With Potential Development and Commercial Milestone Payments of Over $500 million. The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN) Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, target, TScan, potential, investor, announce, Inc, and the most common words in the summary are: amgen, stock, inc, news, market, price, amgn, . One of the sentences in the summary was: Entera Bio, a former partner of Amgen, announced that both were ending a research collaboration.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #inc #news #market #price #amgn.